321 related articles for article (PubMed ID: 33840229)
1. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
2. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
5. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
6. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
[TBL] [Abstract][Full Text] [Related]
8. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
9. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
12. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Sproule S; Olsson RF; Martin UJ; Goldman M;
Lancet Respir Med; 2019 Jan; 7(1):46-59. PubMed ID: 30416083
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
15. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps.
Matsuno O; Minamoto S
Pulm Pharmacol Ther; 2020 Oct; 64():101965. PubMed ID: 33039667
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
17. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment.
Busse WW; Bleecker ER; FitzGerald JM; Ferguson GT; Barker P; Brooks L; Olsson RF; Martin UJ; Goldman M;
J Allergy Clin Immunol; 2021 Jul; 148(1):266-271.e2. PubMed ID: 33609624
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.
Emson C; Han JK; Hopkins C; Asimus S; Cann JA; Chain D; Wu Y; Reddy Y; McCrae C; Cohen D; Kreindler JL; Werkström V; Jison M; Wagenmann M; Bachert C
Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38715387
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]